Skip to main content
. 2021 Mar 17;11:642229. doi: 10.3389/fonc.2021.642229

Figure 6.

Figure 6

Overexpression of AKT increased resistance of A2780/CDDP-shACLY cells to cisplatin. (A) Western blotting was used to confirm the effectiveness of AKT overexpression by plasmid in A2780/CDDP-NC and A2780/CDDP-shACLY cells. (B) The 24 h IC50 of cisplatin of A2780/CDDP-NC-NC, A2780/CDDP-NC-AKT, A2780/CDDP-shACLY-NC and A2780/CDDP-shACLY-AKT was 34.33 (33.04–35.74), 38.06 (34.39–42.95), 20.72 (18.83–22.90), and 29.86 (27.38–32.86) μM, respectively; 48 h IC50 of these cells were 27.90 (25.78–30.21), 25.06 (23.07–27.22), 11.86 (11.06–12.70), and 21.56 (18.96–24.44) μM, respectively; 72 h IC50 of these cells were 12.46 (10.88–14.21), 14.26 (12.85–16.74), 2.933 (2.552–3.340), and 9.891 (8.613–11.29) μM, respectively. (C) Apoptosis analysis on A2780/CDDP-NC-NC, A2780/CDDP-NC-AKT, A2780/CDDP-shACLY-NC, and A2780/CDDP-shACLY-AKT cells with the treatment of 20 μM cisplatin on different time. Quantitive analysis of apoptotic ratio by flowjo V10 software. Statistical analysis was performed using Student's t-test. (D) Western blotting was used to detect the expression of PI3K/AKT relative proteins of A2780/CDDP-NC-NC, A2780/CDDP-NC-AKT, A2780/CDDP-shACLY-NC, and A2780/CDDP-shACLY-AKT cells treated with 20 μM cisplatin for 48 h, the bands were quantified and analyzed. The bands were quantitated with Image J software, statistical analysis was performed using Student's t-test. All cell experiments were repeated three times at least. *P < 0.05, **P < 0.01, and ***P < 0.001 for statistical analysis of the indicated groups.